Charles Schwab Investment Management Inc. Decreases Holdings in OPKO Health, Inc. (NASDAQ:OPK)

Charles Schwab Investment Management Inc. lowered its position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 16.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,212,355 shares of the biotechnology company's stock after selling 835,569 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.60% of OPKO Health worth $6,276,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. CIBC Asset Management Inc increased its holdings in shares of OPKO Health by 79.1% in the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 8,978 shares during the last quarter. Algert Global LLC acquired a new stake in OPKO Health during the second quarter worth $44,000. Private Advisor Group LLC increased its stake in OPKO Health by 242.7% during the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 25,000 shares during the last quarter. Ground Swell Capital LLC acquired a new stake in OPKO Health during the third quarter worth $63,000. Finally, Comerica Bank increased its stake in OPKO Health by 125.0% during the first quarter. Comerica Bank now owns 90,000 shares of the biotechnology company's stock worth $108,000 after acquiring an additional 50,000 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Piper Sandler reissued an "overweight" rating and set a $3.00 target price on shares of OPKO Health in a research note on Tuesday, September 17th. HC Wainwright reissued a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research note on Thursday, September 26th. Finally, Barrington Research reissued an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a research note on Friday, November 8th.

Insider Transactions at OPKO Health

In related news, CEO Phillip Md Et Al Frost bought 500,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The stock was purchased at an average cost of $1.56 per share, for a total transaction of $780,000.00. Following the completion of the acquisition, the chief executive officer now owns 212,411,477 shares in the company, valued at approximately $331,361,904.12. This trade represents a 0.24 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders bought a total of 1,179,255 shares of company stock worth $1,825,855 over the last ninety days. Company insiders own 47.26% of the company's stock.

OPKO Health Trading Up 3.1 %

Shares of OPK traded up $0.05 during midday trading on Thursday, hitting $1.64. 5,562,705 shares of the stock were exchanged, compared to its average volume of 6,812,811. OPKO Health, Inc. has a 52-week low of $0.85 and a 52-week high of $1.76. The stock has a fifty day simple moving average of $1.53 and a 200 day simple moving average of $1.47. The firm has a market cap of $1.12 billion, a P/E ratio of -9.13 and a beta of 1.62. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.